Molecular evidence of coinfection with acute respiratory viruses and high prevalence of SARS-CoV-2 among patients presenting flu-like illness in Bukavu city, Democratic Republic of Congo

Patrick Bisimwa Ntagereka^{1*}, Rodrigue Ayagirwe Basengere¹, Tshass Chasinga Baharanyi^{2,3}, Théophile Mitima Kashosi^{1,2}, Jean-Paul Chikwanine Buhendwa^{2,4}, Parvine Basimane Bisimwa^{2,4}, Aline Byabene Kusinga^{2,4}, Yannick Mugumaarhahama¹, Dieudonné Wasso Shukuru¹, Simon Baenyi Patrick¹, Ronald Tonui⁵, Ahadi Bwihangane Birindwa¹, Denis Mukwege^{2,6}

¹*Université Evangélique en Afrique, Molecular Biology Laboratory, Bukavu Democratic Republic of Congo*

²*Université Evangélique en Afrique, Faculty of Medicine, Bukavu Democratic Republic of Congo*

³*Panzi General Referral Hospital, Pathological Anatomy, Bukavu Democratic Republic of Congo*

⁴*Panzi General Referral Hospital, Department of Infectiology, Bukavu Democratic Republic of Congo*

⁵*Pan African University, Institute of Basic Sciences, Technology and Innovation, Department of Molecular Biology and Biotechnology, Nairobi, Kenya*

⁶*Panzi General Referral Hospital, Gynaecology and General Surgery, Bukavu Democratic Republic of Congo*

Corresponding author: Patrick Bisimwa Ntagereka

Université Evangélique en Afrique, Molecular Biology Laboratory, Bukavu Democratic Republic of Congo, PO Box 3323,

Email address: patrick.ntagereka@gmail.com

Abstract

The coronavirus 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with clinical manifestation cases are almost similar to those of common respiratory viral infections. This study determined the prevalence of SARS-CoV-2 and other acute respiratory viruses among patients with flu-like symptoms in Bukavu city Democratic republic of Congo. We screened 1352 individuals with flu-like illnesses seeking treatment in 10 health facilities. Nasopharyngeal swabs specimens were collected to detect SARS-CoV-2 using real-time reverse transcription-polymerase chain reaction (RT-PCR) and 10 common respiratory viruses were detected by multiplex reverse transcription polymerase chain reaction assay. Overall, 13.9% (188/1352) patients were confirmed positive for SARS-CoV-2. Influenza A 5.6% (56/1352), and Influenza B 0.9% (12/1352) were the most common respiratory viruses detected. Overall more than two cases of the other acute respiratory viruses were detected. Frequently observed symptoms associated with SARS-CoV-2 positivity were shivering (47.8%; OR= 1.8; CI: 0.88-1.35), cough (89.6%; OR=6.5, CI: 2.16-28.2), myalgia and dizziness (59.7%; OR=2.7; CI: 1.36-5.85). Moreover, coinfection was observed in 12 (11.5%) specimens. SARS-CoV-2, and Influenza A were the most co-occurring infections, accounting for 33.3% of all positive cases. This study demonstrates cases of COVID-19 infections co-occurring with other acute respiratory infections in Bukavu city during the ongoing outbreak of COVID-19. These data emphasize the need for routine testing of multiple viral pathogens for better prevention and treatment plans.

Keywords: SARS-CoV-2, respiratory viruses, flu-like symptoms, coinfection; Bukavu city.

1. INTRODUCTION

The world is facing a pandemic caused by the coronavirus disease 2019 (COVID-19), with over 136 million confirmed cases, including approximately 2,941,128 deaths globally as of Apr 13 2021¹. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, that emerged in Wuhan, China, in December 2019². SARS-CoV-2 infection is generally asymptomatic³, although in most confirmed cases, it may manifest itself with non-typical symptoms, including fever, cough, sore throat^{3,4,5}, which are known to be present in common cold. Additionally, anosmia and ageusia may be observed^{6,7}.

The Democratic Republic of the Congo (DRC), with an estimated population of 86 million, reported the first COVID-19 case on March 10, 2020, in Kinshasa city. While in Bukavu, a city whose population is estimated above 1.13 million, registered the first case of COVID-19 from arriving travelers in March 2020. Due to delay in quarantine measures and the failure in applying ministry of health guidelines for containment of the pandemic, DRC had recorded 55774 confirmed cases and 1061 deaths as of 4th September 2021 in all 26 provinces, including South Kivu.

South Kivu is characterized by a high population density, poor health infrastructure and limited access to COVID-19 diagnostic tests. This places South Kivu among the high-risk provinces in DRC. Previous studies have reported high seroprevalence of SARS-Cov-2 among health workers and travelers in Bukavu city, suggesting a high circulation of SARS-CoV-2 within this city^{8,9}.

Diagnostic facilities for viral infections in DRC's provinces, and in particular South Kivu are scarce. This prevents systematic screening of individuals who are asymptomatic or present mild symptoms of COVID-19 (<https://ourworldindata.org/coronavirus-testing>). This challenge further hampers strategies in the evaluation of the spread of SARS-CoV-2 within the population.

Currently, COVID-19 ‘gold’ test, which entails reverse transcription-polymerase chain reaction (RT-PCR) as recommended by World Health Organization^{3,10}, focuses on symptomatic cases, and hence, accurate estimate of the incidence cannot be obtained.

The research on the clinical characteristics of COVID-19 in most African countries has shown that fever and cough are the most common symptoms associated with COVID-19 diagnosis. Aside from these signs, fatigue, difficulty in breathing, sore throat, headache, and other atypical symptoms have been reported.

The glaring similarity between these clinical signs with those of other respiratory viral infections¹¹ reduces the diagnostic efficiency and treatment of COVID-19 cases. This may lead to regular epidemics with pneumonia and bronchitis cases, severe respiratory failure, and even death¹².

As the COVID-19 cases continue to rise, several cases of flu-like illness have been reported in Bukavu city by the Provincial Ministry of Health from December 2020 to April 2021.

Therefore, identifying SARS-CoV-2 and pathogens responsible for respiratory infections is key in the prevention of COVID-19 spread. This could improve patient management and reduce patient isolation duration, particularly for those infected with other common respiratory viruses.

Thus, this study investigated the prevalence of SARS-CoV-2, Influenza A and B, and other acute respiratory viruses among local patients with flu-like symptoms. These include but were not limited to patients presenting a sudden onset of a fever of (>38 °C) and a cough or sore throat who were seeking treatment at different health structures in Bukavu city.

99

100 **2. METHODS**

101 **2.1 Study area**

102 This study was carried out in Bukavu, the capital city of South Kivu province in eastern DRC.
 103 The city is lying at the extreme south-western edge of Lake Kivu and separated from Rwanda by
 104 the outlet of the Ruzizi River. As of 2020, Bukavu had an estimated urban population of
 105 1,133,371. (<https://populationstat.com/democratic-republic-of-the-congo/bukavu>). Moreover, the
 106 city is characterized by a tropical wet and dry climate with 1498 m of altitude above sea level
 107 and an average rainfall of about 1224 mm annually. Patients were recruited from December
 108 2020 to May 2021 in 10 health facilities such as BIOPHARM Health Centre, Panzi General
 109 Reference Hospital, Saint Vincent polyclinic, MUHUNGU Health Centre, DIOCESAIN Centre,
 110 Saint Luc polyclinic, 5th CELPA Health Centre, SOS Medical Centre, Nyantende Hospital, and
 111 CHAI Health Centre.

112 **2.2 Study design, participants, and sample collection**

113 A cross-sectional study was adopted. Collection of swab samples to confirm COVID-19 disease
 114 among patients with flu-like symptoms defined as an outpatient with a sudden onset of a fever
 115 >38 °C, a cough or sore throat seeking treatment at the different health facilities. Only
 116 individuals with flu-like disease symptoms, aged ten years and above, and able to give consent
 117 were considered for sample collection the interview. Personal data such as age, sex, occupation,
 118 and residence were recorded prior to collecting oropharyngeal swab samples. Collected samples
 119 were put in a 2ml tube containing 2 milliliters of Sample Storage Reagent (Ansure,

Biotechnology) composed of 0.9% of normal saline raisin, and stored in -40°C before SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction amplification.

A total of 1352 Oropharyngeal samples were collected and shipped daily in ice to the Molecular Biology laboratory of the Université Evangélique en Afrique (UEA). The data collection followed ethical guidelines applied for human biological data collection and processing during the study.

2.3 Molecular detection of SARS-CoV-2

Viral RNA was extracted from swabs samples within 1–24 hours following sample collection using innuPREP Virus TS RNA kit (Analytik Jena, Berlin, Germany) according to the manufacturer's instructions. The real-time reverse transcriptase-polymerase chain reaction (RT-PCR) tests for SARS-CoV-2 were performed using TIB MOLBIOL Sarbeco E-gene Plus EAV PCR Kit (Olfert Landt, Berlin Germany). Briefly, this entailed a 20 µL reaction mix comprising 10 µL of 2x Reverse transcriptase master Mix, 0.5 µL of extraction control EAV, 0.5 µL of PSR reagent (SARS-CoV-2 probes and primers mix targeting the viral E gene), 5 µL of the extracted RNA and the volume was adjusted to 20 µL with nuclease free water.

The cDNA synthesis step was conducted by incubating the mixture at 55°C for 5 minutes. RT-PCR reactions with an initial denaturation step at 95°C for 5 min, followed by cycling steps of 95°C for 5 seconds, primer annealing at 60°C for 15 seconds, and an extension step of 72°C for 15 seconds. All the RT-PCR reactions were carried out in LightCycler® 96 Instrument (Roche, Life Science). A sample was considered positive if the threshold (Ct value) is <35 while any sample with threshold (Ct value) >35 was considered as negative.

2.4 Detection of common acute respiratory viruses by Multiplex RT-PCR assays

Each RNA sample was subjected to multiplex RT-PCR amplification using the ARVI Screen Real-TM Multiplex Detection kit (Sacace Biotechnology, Italy) on a Lightcycler 96 detection system (Roche, Germany). The panel was specifically developed to identify ten viruses including human respiratory syncytial virus (hRSV); human metapneumovirus (hMpv); human parainfluenza virus-1-4 (hPiv-1-4), OC43, E229, NL63 and HKUI human coronavirus (hCov); human rhinovirus (hRv); human B, C, and E adenovirus (hAdv), human bocavirus (hBov) as well as Influenza A and B within 1 hour. The assay comprised reverse transcription and multiplex RT-PCR Amplification.

The cDNA synthesis was performed in a 40 µL mix containing 5 µL RT-G-mix-1, 6 µL of Reverse transcriptase (M-MLV), 9 µL of RT-Mix, and 20 µL of RNA as a template. The cDNA libraries were constructed by incubating the reaction mix at 37°C for 30 minutes in PeQlab thermocycler, (peqSTAR, VWR). The cDNA samples were diluted in half with T.E. buffer for immediate use in multiplex RT-PCR amplification or storage at -20°C for future analysis.

In addition, the multiplex Real-Time amplification setup was carried. Each mix contained primers directed against regions of acute respiratory viral infection (ARVI). For each mix, three controls were also included, such as negative, positive and internal control.

Real-time RT-PCR assays were performed in a 25 µL reaction comprising 10 µL of PCR-mix 1 containing specific primers for each virus, 5 µL of PCR-Mix-FRT and 10 µL of template cDNA. The cycling parameters entailed 95 °C initial denaturation for 15 min followed by 40 cycles of 95 °C denaturation for 10s, 54°C annealing for 25s and extension at 72 °C for 25s. We set our threshold value for positive cases of ARVI pathogens at any value less than 35.

The negative cases of an ARVI were assessed when the threshold value (Ct) of the tested sample is absent (not determined) or if the Ct value exceeds 35.

2.5 Data analysis

Collected data were encoded in Microsoft® Excel® data management tool combining the results of SARS-CoV-2 RT-PCR and other respiratory virus assays and data obtained from the questionnaire. Prior to statistical analyses, all personal identification data were eliminated. Descriptive statistics were calculated for all of the variables, including the RT-PCR prevalence results. We assessed the associations between SARS-CoV-2 and other respiratory viruses RT-PCR results (positive or negative) with age, sex, symptom, exposure and morbidity using the Chi-Squared test. The odds of being a positive case based on RT-PCR results were then modeled as a function of the dichotomous risk factors measures, using logistic regression models. All variables with p-values of ≤ 0.05 were considered statistically significant. The R. Console statistic software (version 4.0.0) was used to perform the analysis.

3. RESULTS

3.1 SARS-CoV-2 and common acute respiratory infection prevalence and associated

Symptoms in patients with flu-like symptoms from nine health structures

In total, 1352 individuals presenting flu-like illness were examined, all of whom resided in the Bukavu city. Among these were 696 males (51.4%) and 656 females (48.5%). The majority (89.6%) being adults. A high proportion (63.3%) were those recorded in BIOPHARM medical center. The SARS-CoV-2 was detected in 188 representing a positivity rate of 13.9%. The prevalence of SARS-CoV-2 was higher in females (14.6 %) compared to males (13.3%). The age range of the SARS-CoV-2-positive patients was 176(14.5%) out 1212 adults and 12(8.6%) in young (less than 18 years).out of 140.

Influenza A and B viruses were diagnosed respectively in 76 (5.6%) and in 12 (0.9%) samples. Multiplex RT-PCR test detected Human parainfluenza 1-4 (hPiV 1-4) in 10 (0.7%) patients while human Metapneumonia virus (hMpv) was present in 5 (0.4%) patients. Additionally, human Coronavirus (hCoV), human Rhinovirus (hRV) and human Adenovirus (hAdV) were identified in 3 (0.2%) samples for each while only 1(0.07%) patient was identified to be infected with Human Bocovirus (hBoV).

Of all health facilities, Panzi General Reference (Panzi HGRP) recorded the highest SARS-CoV-2, 12 (23.1%), and influenza B 4 (7.7%) cases (Table 1).

207 **TABLE 1** Frequency of SARS-CoV-2 and other respiratory viruses detected according to sex, age and health facility

Variables	Number sampled	SARS-CoV- 2 +	INFL. A +	INFL. B +	hMpv	hPiV 1-4	hCoV	hRV	hAdV	hBoV
Gender										
F	696	101(14.6%)	40(5.8 %)	8(1.2 %)	3(0.4 %)	7(1.0 %)	1(0.1 %)	2(0.3%)	1(0.1%)	1(0.1%)
M	656	87(13.3%)	36(5.5%)	4(0.6 %)	2(0.3 %)	3(0.5 %)	2(0.3 %)	1(0.2%)	2(0.3 %)	0(0 %)
Age range										
Adult	1212	176(14.5%)	60(5.0%)	12(1.0 %)	4(0.3 %)	8(0.7 %)	3(0.2 %)	3(0.2)	3(0.2 %)	1(0.1 %)
Young	140	12(8.6%)	12(8.6%)	0(0 %)	1(0.7 %)	2(1.4 %)	0(0%)	0 (0%)	0(0%)	0(0%)
Health structures										
Biopharm HC	856	116(13.6%)	48(5.6%)	4(0.5 %)	1(0.1 %)	4(0.5 %)	0(0 %)	0(0%)	0(0%)	1 (0.1%)
5 th CELPA HC	72	8(11.1%)	4(5.6 %)	0(0 %)	1 (1.4%)	2(2.8%)	1(1.4 %)	1(1.4%)	2(2.8%)	0(0%)
Panzi GRH	52	12(23.1%)	0(0%)	4(7.7%)	2(3.8%)	0(0%)	2 (3.8 %)	0 (0%)	0(0%)	0(0%)
CHAI HC	64	4(6.3%)	4 (6.3 %)	0(0 %)	0 (0)	0 (0 %)	0 (0 %)	0 (0 %)	0(0 %)	0(0 %)
SOS HC	88	16(18.2%)	4(4.5%)	0 (0%)	0 (0 %)	0 (0 %)	0 (0 %)	0 (0 %)	0(0%)	0(0%)

Nyantede Hospital	76	12(15.8%)	4(5.3%)	0(0 %)	0 (0 %)	0(0 %)	0 (0 %)	1(1.3 %)	0(0%)	0(0%)
Muhungu dios.HC	20	4(20.0 %)	0(0%)	0(0%)	0(0%)	0 (0%)	0(0%)	0(0%)	0(0%)	0(0%)
St Luc HC	24	8(33.3 %)	4(16.7 %)	0(0 %)	1 (4.2%)	2(8.3%)	0(0%)	1(4.2%)	1(4.2%)	0(0%)
Muhungu HC	28	8(2.9 %)	4(1.4 %)	4(1.4%)	0(0%)	2 (0.7%)	0(0%)	0(0%)	0(0%)	0(0%)
Total N (%)	1352	188 (13.9)	76 (5.6)	12 (0.9)	5(0.4)	10(0.7)	3(0.2)	3(0.2)	3(0.2)	1(0.07)

208

209

210

3.2 Profiles of SARS-CoV-2 and other respiratory infection positive patients and associated clinical symptoms

The most frequent symptom in COVID-19 was coughing (89.6%), followed by headaches (77.6%), asthenia (67.2%), high fever (52.2%), as well as myalgia (59.7%). Hypertension (9%), obesity (6%), and diabetes (6%) were the most frequently reported comorbidities in COVID-19 positive individuals. More than half of influenza A-positive patients experienced fever, cough, and headache and were asthenic, hypertensive and diabetics. However, all influenza B infected patients experienced headaches (100%) while more than half presented fever, coldness, cough, breathing difficulties, asthenia, myalgia, anorexia, and sputum (Supplementary materials Table 1). The statistical analysis revealed statistically significant association between COVID-19 with some symptoms such as shivering (47.8%; OR= 1.8; CI: 0.88-1.35; p=0.024), cough (89.6%; OR=6.5, CI=2.16-28.2; p=0.003), myalgia and dizziness (59.7%; OR=2.7; CI: 1.36-5.85, p=0.006) (Table 2).

Comparative analysis between SARS-CoV-2 positive and negative individuals showed that patients who have been in contact with infected persons presented a higher risk of being infected by SARS-CoV-2 were the one with close contact (OR=2.40; CI: 0.43-13.45), followed workers in hospitals (OR=1.78; CI: 0.34-8.43) and patient with diabetes (OR=1.17; CI: 0.29-3.93) than negative individuals. However, none of these factors were statistically significant. Additionally, no statistical difference was found between gender and commodities variables when compared SARS-CoV-2 and negative patients (p<0.05) (Table 2).

TABLE 2: Association of flu-like symptoms with SARS-CoV-2 positivity among flu-like patients seeking treatment in different health facilities

Variables	Negative covid19 N= 1164(%)	Positive Covid19 N= 188(%)	OR (CI)	p value
Symptoms (%)				
Fever	512 (44.1%)	98 (52.2%)	1.1 (0.560-2.282)	0.734
Coldness	531 (45.6%)	98 (52.2%)	0.9 (0.456- 1.856)	0.816
Shivering	371 (31.9%)	88 (47.8%)	1.8 (0.88 - 1.35)	0.0246**
Sweating	268(23.0%)	56 (29.9%)	1.3 (0.603- 3.69)	0.452
Cough	764(65.6%)	168 (89.6%)	6.5 (2.161- 28.207)	0.003***
Breathing difficulties	271(23.3%)	45 (23.9%)	0.7 (0.321-1.814)	0.590
Essoufflés	233(20.0%)	17 (9.0%)	0.3(0.107-1.094)	0.0992
Headaches	793(68.1%)	146 (77.6%)	1.6 (0.738-3.821)	0.242
Asthenia	560(56.7%)	126 (67.2%)	1.6(0.804-3.487)	3.487
Myalgia	478(41.1%)	112 (59.7%)	2.7(1.363-5.859)	0.006***
Anorexia	314(27.0%)	73 (38.8%)	1.5 (0.743-3.283)	0.232
Sputum	194(16.7%)	42 (22.4%)	0.8(0.360-1.926)	0.716
Dyspnea	164(14.1%)	19 (10.4%)	0.6 (0.236-1.772)	0.461
Expositions (%)				
Stay in high risk areas	116 (10.0)	33 (17.9)	1.09 (0.31- 2.81)	0.85
Close contact	48 (4.1)	11 (6.0)	2.40 (0.43-13.45)	0.29
Work in hospitals	81 (7.0)	17 (9.0)	1.78 (0.34-8.43)	0.46
Comorbidities (%)				
HIV infection	8 (0.7)	0 (0.0)	-	-
Arterial hypertension	112 (9.6)	17 (9.0)	0.82 (0.21-2.57)	0.75
Obesity	30 (2.6)	11 (6.0)	0.76 (0.03-6.16)	0.81
Diabetes	69(5.9)	11 (6.0)	1.17 (0.29-3.93)	0.80
Chronic respiratory dis.	26 (2.2)	3 (1.5)	0.56 (0.02-3.97)	0.61
Cardio pathology	8 (0.7)	0 (0.0)	-	-
Chronic kidney dis.	13 (1.1)	0 (0.0)	-	-
Nero pathology	5 (0.4)	1.5	0.00 (0.00-0.001)	0.98

***: highly significant; **: Very significant; *: Significant

3.3 Logistic regression analysis for factors associated with Influenza A and B positivity

The logistic regression analysis revealed that 53.3% (OR=1.51; IC=0.46-4.98) of Influenza A

239 negative patients were inversely correlated with cold compared with 16.7% in influenza A
240 positive patients. However, there were no significant differences in other factors for influenza A
241 and B infection rates ($p > 0.05$) (Table 3).

	INFL A		INFL. A		INFL B		INFL. B	
	Neg. (N=1276)	Pos. (N=76)	OR (IC)	p	Neg. (N=1340)	Pos. (N=12)	OR (IC)	p
Symptoms (%)								
Fever	48.2	58.3	1.51 (0.46-4.98)	0.558	49.0	51.2	1.04 (0.21, 5.22)	1.000
Coldness	53.3	16.7	0.18 (0.04-0.83)	0.017**	50.3	51.5	0.99 (0.20, 4.94)	1.000
feeling								
Shivering	40.1	25.0	0.50 (0.13-1.92)	0.369	38.8	51.5	1.58 (0.32, 7.91)	0.682
Sweating	24.8	25.0	1.01 (0.26-3.95)	1.000	25.2	0.0	-	-
Cough	77.4	58.3	0.41 (0.12-1.38)	0.163	76.2	51.3	0.31 (0.06, 1.57)	0.155
Breathing	22.6	25.0	1.14 (0.29-4.47)	1.000	22.4	51.2	3.45 (0.69, 17.38)	0.135
difficulties								
Essoufflés	16.1	25.0	1.74 (0.44-6.95)	0.425	17.0	0.0	-	-
Headaches	71.5	66.7	0.80 (0.23-2.80)	0.745	70.7	100.0	-	-
Asthenia	59.1	50.0	0.69 (0.21-2.25)	0.556	58.5	51.5	0.71 (0.14, 3.55)	0.697
Myalgia	48.9	25.0	0.35 (0.09-1.34)	0.139	46.9	51.5	1.13 (0.23, 5.66)	1.000
Anorexia	31.4	25.0	0.73 (0.19-2.83)	0.755	30.6	51.5	2.27 (0.45, 11.37)	0.379
Sputum	25.5	8.3	0.26 (0.03-2.13)	0.295	23.8	51.1	3.20 (0.64, 16.09)	0.155
Dyspnea	16.1	25.0	1.74 (0.44-6.95)	0.425	17.0	0.0	-	-
Expositions (%)								
Stay in high risk areas	14.6	16.7	1.17 (0.24-5.74)	0.692	15.0	0.0	-	-
Close contact	4.4	0.0	-	-	4.1	0.0	-	-
Work in hospitals	5.1	0.0	-	-	4.8	0.0	-	-
Comorbidities								

(%)									
Immunosuppression	0.7	0.0	-	-	0.7	0.0	-	-	-
Hypertension	9.5	16.7	1.91 (0.38-9.66)	0.346	10.2	0.0	-	-	-
Obesity	2.2	8.3	4.06 (0.39-42.37)	0.288	2.7	0.0	-	-	-
Diabete	7.3	16.7	2.54 (0.49-13.21)	0.249	8.2	0.0	-	-	-
Chronic Resp. dis.	3.6	0.0	-	-	3.4	0.0	-	-	-
Chronic Cardiac dis.	0.0	0.0	-	-	0.0	0.0	-	-	-
Chronic kidney dis.	0.7	0.0	-	-	0.7	0.0	-	-	-
Chronic liver dis.	0.0	0.0	-	-	0.0	0.0	-	-	-
Chronic neurologic dis.	0.7	0.0	-	-	0.7	0.0	-	-	-

**: Very significant

244

245

246

3.4 Coinfection patterns of COVID-19 and other acute respiratory viruses

During this investigation, it was found six coinfection patterns. Out of the 113 cases of infected acute respiratory patients, 12 (11.5%) cases were co-infected with different acute respiratory viruses. A high frequency of coinfections pathogens involved SARS-CoV-2 and Influenza A, accounting for 33.3% of all coinfection cases. Additionally, 3 cases (25%) of hMPiV positive cases were co-infected with hCoV followed by 2 cases (16.6%) of SARS-CoV-2 co-infected with Influenza B (Table 4).

TABLE 4: Co-infection of SARS-CoV-2 with others respiratory viruses in Flu-like symptomatic patients

<i>Number</i>	<i>Virus types</i>	<i>Co-infectious viruses</i>	<i>Cases</i>
1	hMPV+hPiV 1-4	2	1
2	hMPV+hCoV	2	3
3	HBoV+Inf. A	2	1
4	SARS-CoV-2+Inf. B	2	2
5	SARS-CoV-2+Inf. A	2	4
6	SARS-CoV-2+hMPiV	2	1

4. DISCUSSION

COVID-19 first reports in DRC emerged towards the beginning of March 2020 and there has been an upsurge of the cases ever since then nationally. SARS-COV-2 infections in South Kivu province soared from April to December 2020. This is the period when flu-like illnesses peaks. It was therefore vital to investigate the presence of SARS-CoV-2 among local patients with flu-like illnesses seeking treatment in various health facilities. This may help us to better control the epidemic outbreak and correctly handle other acute respiratory infections. Participants in this study included 696 males (51.4%) and 656 females (48.5%). The majority were adults 1212 (89.6%).

In this study, a total of 188 participants were confirmed to be COVID-19 positives with positivity rate of 13.9%. The infection rate found from this study is higher than the one found in a previous study conducted in China where only 0.3% of patients with influenza-like illnesses were found to be COVID-19 positive¹³. Similarly, these results are not consistent with the ones reported in South Kivu, DRC, in which SARS-CoV-2 antibodies were detected in 148 (41.2%) health workers from the Panzi General Reference Hospital (HGRP)⁹. This difference could probably be explained by the type of test and study population. The previous study from HGRP was detecting only antibodies (exposure) and focusing only on asymptomatic health workers while in this study, we examined individuals presenting flu-like illness seeking treatment in different health facilities.

In addition, 8.3% of the flu-like illness patients were tested positive for other respiratory viruses. These results emphasize the importance of simultaneous diagnosis of other acute respiratory viral pathogens, particularly in a mild epidemic area and during the current COVID-19 pandemic.

Among the acute respiratory viral pathogens, Influenza A and influenza B viruses were the most detected respectively in 76 (5.6%) and 12 (0.9%) patients with flu-like symptoms and COVID-19 negative. This infection rate is relatively lower than those reported in Shanghai in which influenza A and B were detected in 40.4% and 14.3% of patient respectively¹⁴. In Chongqing, 65.7% cases of Influenza A and 34.1% of Influenza B were reported in individuals with flu-like symptoms¹⁵. This differences could be explained by the difference in targeted population, the previous was focused mostly while in the last study the majority were children and young people. As the considered area face different agro-ecological conditions, this may lead to different rate of infection. However, findings from this study are in agreement with a recent study revealing a higher incidence of influenza infections in children and adolescents compared to old individuals¹⁶.

Furthermore others respiratory pathogens were detected including hPiV 1-4, hPiV 1-4 10(0.7%), hMPiV 5(0.4) and the other virus with 3 cases (0.2%) each. Similar results were obtained in different studies in Costa Rican and China¹⁷. In all the cases, adult persons tended to be mostly affected compared to young people although no statistical differences were found.

A weak association was noted in patients infected with respiratory viruses and clinical signs such as cough, headaches, asthenia, coldness feeling, fever, shivering, and myalgia. This result is in agreement with the finding from Monto et al.¹⁸ that revealed cough associated with fever to be the most frequent symptoms with influenza infection. However, our findings are inconsistent with a previous study focused on clinical features of COVID-19 and Influenza, which demonstrated that symptoms like anosmia, dysgeusia, diarrhea, frontal headache and bilateral cracklings sounds were more frequent in COVID-19 while sputum production, dyspnea, sore throat, conjunctivitis, hyperthermia, tearing, vomiting and rhonchi sounds were more frequent in

influenza infection¹⁹. A subsequent study with a larger sample and follow up of patients would allow to establish clinical signs of similarities and differences between infection with COVID-19 and infection with other respiratory viruses. This can help practically in the areas under equipped for the biological diagnosis.

In this study, gender and comorbidities did not significantly influence the COVID-19 rate. This is similar with previous studies showed that gender was not associated with the SARS-CoV-2 infection rate^{20, 21}.

The risk of being infected by SARS-CoV-2 increased in patients who have been in contact with diseased persons (OR=2.4). This is in accordance with the fact that in resource-limited areas, including South Kivu province, quarantine of infected individuals often occurred at home, enabling onwards transmission within households.

People of all ages are susceptible to SARS-CoV-2. However, previous findings have confirmed that adults, specifically older men are more likely to be affected and subsequently suffer from severe pneumonia, pulmonary oedema, acute respiratory distress syndrome, multiple organ failure, and death^{5, 22,23}. Although it appeared that all ages of the population are susceptible to SARS- CoV-2 infection, but the median age of infection was in adult persons (around 50 years). This is in agreement with previous research revealing the median age of infection to be around 50 years²⁰, and considering the range of African population.

In general, there are no striking differences in the clinical behavior and severity between the different Influenza A and B viruses affecting patients. The only significant clinical symptom with negative relationship to Influenza A virus was feeling cold (OR= 0.18, p=0.017) where the majority of influenza A negative individuals were feeling cold. Our data do not show differences in clinical manifestation compared with other previous descriptions in the literature. However,

three clinical symptoms were relevant for Influenza A, including fever, cough, headache, feeling cold. Similar results were reported in a previous study in Costa Rica¹⁶. Among the 12 patients who were Influenza A type positive in our study, all (100%) had a headache, and more than half presented the remaining symptoms such as Fever, Coldness, Shivering, Sweating, Cough, Breathing difficulties, essoufflés, Asthenia, myalgia, anorexia, sputum, and Dyspnea. No respiratory and cardiac failure was observed to be associated with Influenza infection. This result is in contrast with previous studies that have reported 16% of cases of seasonal Influenza occurring in clinical pulmonary patients²⁴ and 25.2% in cardiac failure²⁵. Moreover, 12 (11.5%) cases co-infected with other acute respiratory viruses were reported. The highest coinfections pathogens were SARS-CoV-2 and Influenza A, accounting for 33.3% of all coinfection cases. The high coinfection rate between SARS-CoV-2 and Influenza virus can probably be explained by restrictions in applying barrier measures such as wearing masks, hand washing, social distance, and hand-sanitizing of infected person. This could further be due to the seasonality nature of the influenza virus which peaks between December and April, corresponding to the winter period. This observation is supported by a previous study conducted by Leung et al.²⁶. However, our finding is in contrast with previous studies^{27,28} whose findings show a decrease in seasonal influenza cases during the Covid-19 pandemic. In this regard, it would be ideal to have the follow-up of patients co-infected with COVID-19 and other respiratory viruses and to assess their evolution over time; this may also requires another extended study for clinical follow-up of cases.

In addition, in this study, cases of hMPiV co-infected with hCoV were reported. These findings are in accordance with previous studies suggesting the possible coinfections of multiple respiratory viruses^{29, 30, 31,32}.

This study demonstrates cases of COVID-19 infections co-occurring with other acute respiratory infections in DR Congo. These data on the coinfection of SARS-CoV-2 with respiratory viral pathogens emphasize the need for routine testing of multiple viral pathogens in mild epidemic areas during the current COVID-19 epidemic. Further study is need to evaluate clinical patient with these co-infection and their evolution. Additionally, whether simultaneous viral infection in SARS-CoV-2 patients can potentially drive viral interference or impact disease outcome need further investigation.

5. CONCLUSION

This study analysed the epidemiological patterns of SARS-CoV-2 and different respiratory viruses, and found a high infection rate with COVID-19 and cases of positive common acute respiratory infections in patients presenting flu-like symptoms. Although the current pandemic constitutes a serious public health concern, SARS-CoV-2 may not be considered to be the only pathogen responsible for respiratory tract infection in South Kivu eastern of DRC. Therefore, testing for respiratory viruses should be performed in all patients with respiratory symptoms for effective surveillance of the transmission patterns in the COVID-19 affected areas for optimal treatment to inhibit the rapid spread of the virus

ETHICS STATEMENT

The study protocol was approved by the Interdisciplinary Center of Ethical Research (CIRE) of the Université Evangélique en Afrique (UEA), Ref: CNES 001/DPSK/115PP/2021. Informed consent was obtained from all participants after being signed and the confidentiality of the data was ensured.

CONFLICT OF INTERESTS

377 The authors declare that they have no competing interests.

378 **AUTHOR CONTRIBUTIONS**

379 Patrick Bisimwa Ntagereka completed study design, project administration, data collection,
380 drafted the manuscript.

381 Rodrigue Ayagirwe Basengere completed investigation, data curation, review and the editing the
382 manuscript.

383 Tshass Chasinga Baharanyi completed investigation, and review of the manuscript.

384 Théophile Mitima Kashosi completed data curation, review and editing of the manuscript.

385 Jean-Paul Chikwanine Buhendwa completed investigation, data collection review and editing.

386 Parvine Basimane Bisimwa completed conceptualization, writing, and original draft preparation.

387 Aline Byabene Kusunza, investigation, data collection review and editing of the manuscript

388 Yannick Mugumaarhahama completed formal analysis, visualization, writing, and original draft
389 preparation.

390 Dieudonne Wasso Shukuru completed conceptualization, data analysis, writing, review, and
391 editing.

392 Simon Baenyi Patrick completed formal analysis, data curation, writing, and original draft
393 preparation.

394 Ronald Tonui, completed formal analysis, visualization, writing, and original draft preparation.

Ahadi Bwihangane Birindwa completed investigation, data curation, review and editing of the manuscript.

Denis Mukwege, supervised the study, completed project administration, writing, review, and editing the manuscript. All authors approved the manuscript.

ACKNOWLEDGMENTS

We Acknowledge the Université Evangélique en Afrique (UEA) through the Bioscience unit and German Institute for Medical Mission (DIFÄM) for the financial support. Our sincere appreciation goes further to the Provincial Ministry of Health and all the leaders of health structures for facilitating access to sample and data. We also thank you the lab technicians of the Molecular Biology laboratory of UEA for their technical support.

FUNDING SOURCE

This work was partially supported by a grant from the German Institute for Medical Mission (DIFÄM) and by the Université Evangélique en Afrique (UEA) under the grant number 2020-610-CD titled “Projet de formations sur les méthodes de diagnostic de COVID-19 et amélioration de la prise en charge clinique des cas graves”.

REFERENCES

1. World Health Organization (WHOa). Coronavirus disease (COVID- 19): Similarities and differences with Influenza. Q&A (Mar 17 2020). (Accessed on Oct 25 2020). Available from: <https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-similarities-and-differences-with-influenza>.
2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; 579, 270–273.
3. World Health Organization (WHOb). Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases, Interim guidance Mar 2 2020 [Internet]. 2020 [Cited 14/07/2020]. Available from: <https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-2020.4-eng.pdf?sequence=1&isAllowed=y>. <https://doi.org/10.15585/mmwr.mm6942a5> PMID: 33090982.
4. Jung CY, Park H, Kim DW, Choi YJ, Kim SW, Chang TI. Clinical characteristics of asymptomatic patients with COVID-19: a Nationwide cohort study in South Korea. *Int J Infect Dis* 2020; 99:266–8 Available from: <https://pubmed.ncbi.nlm.nih.gov/32771632>. <https://doi.org/10.1016/j.ijid.2020.08.001>.
5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).

6. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol* 2020;77:683–90. <https://doi.org/10.1001/jamaneurol.2020.1127>.
7. Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: common findings in COVID-19 patients. *Laryngoscope* 2020;130(7):1787. <https://doi.org/10.1002/lary.28692>.
8. Katchunga PB, Murhula A, Akilimali P, Zaluka JC, Karhikalembu R, Makombo M, Bisimwa J, Mubalama E. Séroprévalence des anticorps anti-SARS-CoV-2 parmi les voyageurs et travailleurs dépistés à la clinique Saint Luc de Bukavu, à l'Est de la République Démocratique du Congo, de mai en août 2020. *Pan Afr Med J* 2021; 38:93. [10.11604/pamj.2021.38.93.26663](https://doi.org/10.11604/pamj.2021.38.93.26663).
9. Mukwege D, Kusunza BA, MunguAkonkwa E, Dahma H, Dauby N, Cikwanine JPB, Coadou AL, Montesinos I, Bruyneel M Cadière GB, Vandenberg O, Laethem YV. High SARS-CoV-2 Seroprevalence in Healthcare Workers in Bukavu, Eastern Democratic Republic of Congo. *Am J Trop Med Hyg* 2021; 104(4), 1526–1530. doi:10.4269/ajtmh.20-1526.
10. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020a; 25(3): 2000045. doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
11. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; 382(18):1708–1720. doi:10.1056/NEJMoa2002032. PubMed PMID: 32109013.
12. Finianos M, Issa R, Curran MD, Afif C, Rajab M, Irani J, Hakimeh N, Naous A, Hajj M-J, Hajj P, et al. Etiology, seasonality, and clinical characterization of viral respiratory

- infections among hospitalized children in Beirut, Lebanon. *J Med Virol* 2016;88(11):1874–81.
13. Kong WH, Li Y, Peng MW, Kong DG, Yang XB, Wang L, Liu MQ. SARS-CoV-2 detection in patients with influenza-like illness. *Nat Microbiol* 2020; <https://doi.org/10.1038/s41564-020-0713-1>.
14. Kong DC, Wu HY, Zheng YX, Pan H, Jiang CY, Zhang X, Chen J, Wu F. Etiologic and epidemiologic features of acute respiratory infections in adults from Shanghai, during 2015-2017]. *Zhonghua Liu Xing Bing Xue Za Zhi Chinese*. 2019; 10;40(8):904-910. doi: 10.3760/cma.j.issn.0254-6450.2019.08.007.
15. Qi L, Xiong Y, Xiao B, Tang W, Ling H, Long J, Xiao D, Zhao H, Ye S, Chen S, et al. Epidemiological and Virological Characteristics of Influenza in Chongqing, China, 2011-2015. *PLoS One*. 2016;11(12):e0167866.
16. Ávila-Moralesa S, Ospina-Henaob S, Ulloa-Gutierrez R, Ávila-Agüeroa ML. Epidemiological and clinical profile between influenza A and B virus in Costa Rican children. *Int J Infect Dis*; 2021; 105, 763–768.
17. Singh V, Upadhyay P, Reddy J, Granger J. SARS-CoV-2 respiratory coinfections: Incidence of viral and bacterial co-pathogens *Int J Infect Dis* 2021; 105 617–620.
18. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. *Arch Intern Med* 2020; 160:(21), 3243-3247.
19. Zayet S, Lepiller Q, Zahra H, Royer PY, Toko L, Gendrin V, Klopfenstein T. Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. *Microbes and infect* 2020; 22(9), 481-488.

20. Wu Z and McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323, 1239–1242.
21. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol 2020; 92:401–402.
22. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507–13.
23. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; <https://doi.org/10.1001/jama.2020.1585>.
24. Casalino E, Antoniol S, Fidouh N, Choquet C, Lucet J-C, Duval X, et al. Influenza virus infections among patients attending emergency department according to main reason to presenting to ED. A 3-year prospective observational study during seasonal epidemic periods. PLoS ONE 2017; 12(8): e0182191. <https://doi.org/10.1371/journal.pone.0182191>.
25. Maruyama T, Fujisawa T, Suga S, Nakamura H, Nagao M, Taniguchi K, et al. Outcomes and Prognostic Features of Patients With Influenza Requiring Hospitalization and Receiving Early Antiviral Therapy: A Prospective Multicenter Cohort Study. Chest. 2016; 149(2):526-534.doi: 10.1378/chest.14-2768.
26. Leung NHL, Chu DKW, Shiu EYC, Chan KH, McDevitt JJ, Hau JPB et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med 2020; 26, 676–680 <https://doi.org/10.1038/s41591-020-0843-2>.

27. Sakamoto H, Ishikane M, Ueda P. Seasonal Influenza Activity During the SARS-CoV-2 Outbreak in Japan. 2020. JAMA. 2020;323(19):1969-1971. doi:10.1001/jama.2020.617.
28. Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, Tian J, Zhou P, Deng Y, Shang J. The epidemiology and clinical characteristics of coinfection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. J Med Virol 2020. 92(11):2870-2873. doi: 10.1002/jmv.26163.
29. Li X, Li J, Meng L, Zhu W, Liu X, Yang M, Yu D, Niu L, Shen X. Viral etiologies and epidemiology of patients with acute respiratory infections based on sentinel hospitals in Gansu Province, Northwest China, 2011-2015. J Med Virol 2018;90(5):828–35.
30. Ren L, Gonzalez R, Wang Z, Xiang Z, Wang Y, Zhou H et al. Prevalence of human respiratory viruses in adults with acute respiratory tract infections in Beijing, 2005-2007. Clin Microbiol Infect 2009; 15(12):1146–53.
31. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, Li Q, Gu S, Xu T, Li Y, et al. Coinfection with SARS-CoV-2 and Influenza A virus in patient with pneumonia, China. Emerg Infect Dis 2020;26(6):1324–6.
32. Touzard-Romo F, Tapé C, Lonks JR. Coinfection with SARS-CoV-2 and Human Metapneumovirus. Rhode Island Med J 2020;103(2):75–6.